Repatha (evolocumab) lowered the risk of death from any cause by 20% in high-risk adults without a previous heart attack or ...
Managed Healthcare Executive and the Pharmacy Benefit Management Institute (PBMI) are recognizing outstanding professionals in pharmacy benefits with the PBMI Innovators award. We are celebrating ...
The FDA has approved Lilly’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, or non-fatal stroke in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results